NCT06550895

Phase 2Interventional

Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.

View on ClinicalTrials.gov ↗

Timeline

Start date: Sep 16, 2024
Primary completion: Oct 16, 2026
Completion date: Feb 15, 2027
First posted: Aug 13, 2024
Last posted: Oct 24, 2024
Enrollment: 30
Arms / groups: 3 / —
Source: AACT · ctgov ingestion

Drugs studied

lenalidomide
daratumumab
dexamethasone
ciltacabtagene autoleucel
Talquetamab

Indications studied

Multiple Myeloma

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.